Arch Venture Partners
Seattle, Washington
www.archventures.com
Flagship Ventures
Cambridge, Massachusetts
www.flagshipventures.com
Third Rock Ventures
Boston, Massachusetts
www.thirdrockventures.com
Third Rock Ventures, Flagship Ventures and ARCH Venture Partners together led the company's $33 Million Series A round in July 2008.
Agios Pharmaceuticals was founded as part of a seed financing by ARCH Venture Partners and Flagship Ventures with three of the foremost authorities and leaders within the field of cancer metabolism: Lewis C. Cantley, Ph.D., director of the Cancer Center at Beth Israel Deaconess Medical Center and professor of systems biology, Harvard Medical School; Tak W. Mak, Ph.D., the Campbell Family Institute for Cancer Research and the University of Toronto; and Craig B. Thompson, M.D., president and CEO of Memorial Sloan-Kettering Cancer Center.
Agios also received an equity investment from Celgene, Inc. as part of a broad strategic alliance in cancer metabolism initiated by the two companies in April 2010.
In November 2011, Agios announced that it secured $78 million in an oversubscribed Series C financing. Several new, undisclosed investors, including three leading, large public investment funds, joined Agios’ strategic partner Celgene and existing investors ARCH Venture Partners, Flagship Ventures and Third Rock Ventures in this round.